SCHEMBL4394949

SCHEMBL4394949

O=C(O)Cc1cccc(CCc2ccccc2C(=O)O)c1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 2/20 0.51
AKR1B1 P15121 1/20 0.48
ALDH1A1 P00352 2/20 0.48
ADRB2 P07550 1/20 0.48
HTT P42858 1/20 0.47
PPARG P37231 2/20 0.44
PPARA Q07869 2/20 0.44
TSHR P16473 2/20 0.44
MAPT P10636 1/20 0.43
EGFR P00533 1/20 0.43
LCK P06239 1/20 0.43
SLC16A3 O15427 1/20 0.43
KDM4E B2RXH2 1/20 0.43
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
SOX18 P35713 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8701316 0.86 TSHR (0.57) FOLH1AKR1B1PPARGPPARATSHR
SCHEMBL11710019 0.84 HTT (0.57) FOLH1ALDH1A1ADRB2HTTTSHR
SCHEMBL7765745 0.84 FOLH1 (0.54) FOLH1ALDH1A1ADRB2HTTTSHR
SCHEMBL166927 0.83 FOLH1 (0.66) FOLH1ALDH1A1ADRB2HTTTSHR
SCHEMBL29975597 0.83 FOLH1 (0.66) FOLH1ALDH1A1ADRB2HTTTSHR
SCHEMBL4402323 0.83 AKR1B1 (0.62) AKR1B1ALDH1A1HTTTSHRMAPT
Hydrochloric Acid SCHEMBL7699238 0.81 FOLH1 (0.63) FOLH1ALDH1A1ADRB2HTTTSHR
SCHEMBL8702953 0.81 FOLH1 (0.63) FOLH1ALDH1A1ADRB2HTTTSHR
SCHEMBL11118833 0.81 SLC16A3 (0.53) FOLH1ALDH1A1ADRB2HTTSLC16A3
SCHEMBL13877023 0.81 MAOA (0.61) FOLH1ALDH1A1ADRB2HTTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7553809-B2 Fc receptor modulators and uses thereof ILEXUS PTY LIMITED (AU) 2009-06-30 US disclosed
US-20060057144-A1 Fc receptor modulators and uses thereof ILEXUS PTY LIMITED (AU) 2006-03-16 US disclosed
US-6835753-B2 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt ILEXUS PTY LIMITED (AU) 2004-12-28 US disclosed
US-20020061844-A1 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt ILEXUS PTY LIMITED 2002-05-23 US disclosed
US-6355683-B1 ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE ILEXUS PTY LIMITED (AU) 2002-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061844-A1 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt FCGR2A, FCGR1A, FCER2 FOLH1 600/4885AKR1B1 1404/4885ALDH1A1 2926/4885
US-20060057144-A1 Fc receptor modulators and uses thereof FCGR1A, FCER2, FCGR2A FOLH1 1072/4885AKR1B1 2081/4885ALDH1A1 3012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.